Bayer bought gene treatment company Asklepios BioPharmaceutical, typically referred to as AskBio, Oct. 26 in an offer totaling $4 billion.
” In line with our purpose science for a much better life, we are devoted to bringing substantial enhancements for clients through innovation,” Bayer CEO Werner Baumann, stated in a press release. “With this acquisition, Bayer considerably advances the facility of a cell and gene treatment platform that can be at the forefront of breakthrough science, contributing to preventing or perhaps treating diseases triggered by gene flaws and more driving business growth in the future.”.
Under the deal, Bayer will own full rights to AskBios gene therapy platform, which focuses on adeno-associated viruses. Bayer will likewise own AskBios existing gene therapy production platform and take over its different products in scientific screening to treat metabolic, cardiovascular, neuromuscular and main nervous system conditions.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by click on this link.
More short articles on drug store:4 takeaways from the FDA vaccine advisory panel meeting10 drugs that engage poorly with alcoholAstraZeneca, Johnson & & Johnson COVID-19 vaccine trials to resume.
More articles on drug store: Remdesivir becomes very first FDA-approved COVID-19 treatmentConvalescent plasma reveals no benefit for COVID-19 patients in scientific trialA breakdown of the 4 COVID-19 vaccine trials in late-stage screening.
Katie Adams –
Monday, October 26th, 2020
Bayer will pay $2 billion to AskBio upfront, as well as an extra $2 billion in success-based turning point payments.